

Human LILRA1/CD85i/LIR-6 Protein

Cat. No. LIL-HM4A1

Description

Source	Recombinant Human LILRA1/CD85i/LIR-6 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Pro17-Asn461.
Accession	O75019-1
Molecular Weight	The protein has a predicted MW of 51.4 kDa. Due to glycosylation, the protein migrates to 70-80 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

LILRA1, also known as CD85i and LIR-6, is an approximately 70 kDa variably glycosylated transmembrane protein that regulates immune cell activation. Mature human LILRA1 consists of a 445 amino acid (aa) extracellular domain (ECD) with 4 Ig-like domains, a 21 aa transmembrane segment, and a 7 aa cytoplasmic tail. LILRA1 may act as receptor for class I MHC antigens.


Assay Data

Bis-Tris PAGE



Human LILRA1 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC



The purity of Human LILRA1 is greater than 95% as determined by SEC-HPLC.